30-day average of 13 articles · scale −100 to +100
Across 13 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Cencora news is Bullish (+60)
on a scale from −100 to +100.
That is up 19 points from the previous 30 days (+41).
Cencora stock sets specialty-led path for fiscal 2027
AI-generated analysis
Key insights
📈 Cencora reported fiscal fourth-quarter revenue of $88.4 billion, a 5.5% increase from the prior-year quarter.
💰 Adjusted diluted earnings per share surged 21.4% year-over-year to $4.66, driven by higher gross profit and the OneOncology acquisition.
🔄 The company reorganized its fiscal 2027 structure to center on specialty services, which are expected to grow revenue at 9% to 14%.
💵 Cencora raised its quarterly dividend by 10% to $0.66 per share, payable on November 30.
🚀 Management forecasts fiscal 2027 adjusted diluted EPS between $19.40 and $19.75, implying 8% to 10% growth.
🤝 The company plans to acquire American Oncology Network and sell its stake in Profarma to optimize the portfolio.
📈 Bullish signals
💰Cencora reported a significant 21.4% year-over-year increase in adjusted diluted earnings per share to $4.66, driven by higher gross profit and the OneOncology acquisition.
💵The company raised its quarterly dividend by 10% to $0.66 per share, signaling confidence in cash flow generation and shareholder returns.
🔄Management expects the specialty division to be the primary growth engine for fiscal 2027, with revenue projected to grow between 9% and 14%.
🚀Cencora reaffirmed its long-term target of 10% to 14% adjusted diluted EPS growth, maintaining a strong trajectory for shareholder value.
💰The acquisition of OneOncology contributed directly to improved operating performance and supported the transition toward higher-margin specialty services.
Article
Cencora Inc. reported strong fiscal fourth-quarter results on November 4, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% year-over-year to $4.66. The company also posted GAAP EPS of $2.71, a significant turnaround from a loss in the prior period, driven by higher gross profit and the acquisition of OneOncology.
Management has reorganized its reporting structure for fiscal 2027 to prioritize specialty services, which are projected to outpace traditional distribution growth. The specialty division is expected to grow revenue between 9% and 14%, compared to 4% to 6% for the pharmaceutical distribution segment, reflecting a strategic shift toward higher-growth areas.
For fiscal 2027, Cencora forecasts adjusted diluted earnings per share between $19.40 and $19.75, representing 8% to 10% growth from the prior year. The company also raised its quarterly dividend by 10% to $0.66 per share and plans further portfolio moves, including the acquisition of American Oncology Network and the sale of its stake in Profarma.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Cencora Inc. reported strong fiscal fourth-quarter results on November 4, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% year-over-year to $4.66. The company also posted GAAP EPS of $2.71, a significant turnaround from a loss in the prior period, driven by higher gross profit and the acquisition of OneOncology.
Management has reorganized its reporting structure for fiscal 2027 to prioritize specialty services, which are projected to outpace traditional distribution growth. The specialty division is expected to grow revenue between 9% and 14%, compared to 4% to 6% for the pharmaceutical distribution segment, reflecting a strategic shift toward higher-growth areas.
For fiscal 2027, Cencora forecasts adjusted diluted earnings per share between $19.40 and $19.75, representing 8% to 10% growth from the prior year. The company also raised its quarterly dividend by 10% to $0.66 per share and plans further portfolio moves, including the acquisition of American Oncology Network and the sale of its stake in Profarma.
📈 Q4 revenue rose 5.5% to $88.4 billion.
💰 Adjusted EPS surged 21.4% to $4.66.
🔄 Specialty services expected to grow 9-14%.
💵 Dividend increased 10% to $0.66/share.
🚀 FY27 EPS forecast implies 8-10% growth.
📈 Cencora reported fiscal fourth-quarter revenue of $88.4 billion, a 5.5% increase from the prior-year quarter.
💰 Adjusted diluted earnings per share surged 21.4% year-over-year to $4.66, driven by higher gross profit and the OneOncology acquisition.
🔄 The company reorganized its fiscal 2027 structure to center on specialty services, which are expected to grow revenue at 9% to 14%.
💵 Cencora raised its quarterly dividend by 10% to $0.66 per share, payable on November 30.
🚀 Management forecasts fiscal 2027 adjusted diluted EPS between $19.40 and $19.75, implying 8% to 10% growth.
🤝 The company plans to acquire American Oncology Network and sell its stake in Profarma to optimize the portfolio.
Bullish Signals
Adjusted EPS rose 21.4% YoY to $4.66.
Bullish Signals
Cencora reported a significant 21.4% year-over-year increase in adjusted diluted earnings per share to $4.66, driven by higher gross profit and the OneOncology acquisition.
The company raised its quarterly dividend by 10% to $0.66 per share, signaling confidence in cash flow generation and shareholder returns.
Management expects the specialty division to be the primary growth engine for fiscal 2027, with revenue projected to grow between 9% and 14%.
Cencora reaffirmed its long-term target of 10% to 14% adjusted diluted EPS growth, maintaining a strong trajectory for shareholder value.
The acquisition of OneOncology contributed directly to improved operating performance and supported the transition toward higher-margin specialty services.
Cencora Inc. reported strong fourth-quarter results for the period ended September 30, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% to $4.66. The company also posted full-year fiscal figures showing a 5.0% revenue increase to $337.4 billion and a 12.3% rise in adjusted EPS to $17.97, driven by higher gross profit and the contribution from its OneOncology acquisition.
Looking ahead to fiscal 2027, management forecasts adjusted diluted earnings per share growth of 8% to 10%, with revenue expected to expand 3% to 5%. The company has adopted a new reporting structure that highlights specialty pharmaceutical and provider services as the primary growth engine, projecting this segment to deliver 9% to 14% revenue growth and 18% to 21% operating income growth.
In addition to its earnings outlook, Cencora announced a quarterly dividend increase of 10% to $0.66 per share and plans approximately $1.25 billion in additional share repurchases for fiscal 2027. The company also anticipates closing the MWI Animal Health merger with Covetrus by March 31, 2027, and completing the sale of its Profarma stake in the first fiscal quarter.
📈 Q4 revenue rose 5.5% to $88.4 billion.
💰 Adjusted EPS surged 21.4% to $4.66.
🚀 FY2027 adjusted EPS forecast growth of 8-10%.
🔬 Specialty pharma and provider services drive 9-14% revenue expansion.
💵 Quarterly dividend increased 10% to $0.66.
📈 Cencora reported fourth-quarter revenue of $88.4 billion, a 5.5% increase from the prior-year quarter.
💰 Adjusted diluted earnings per share surged 21.4% to $4.66 in the fourth quarter, excluding acquisition and restructuring costs.
🚀 Management forecasts fiscal 2027 adjusted EPS growth of 8% to 10%, reaching $19.40 to $19.75 per share.
🔬 Specialty pharmaceutical and provider services are designated as the core growth driver with projected revenue expansion of 9% to 14%.
💵 The board declared a quarterly dividend of $0.66, representing a 10% increase from the previous quarter.
📉 Cencora plans approximately $1.25 billion in additional share repurchases for fiscal 2027 alongside $3.5 billion in adjusted free cash flow.
🤝 The company expects to close the MWI Animal Health merger with Covetrus by March 31, 2027.
💼 Cencora intends to complete the sale of its Profarma stake during the first fiscal quarter of 2027.
Bullish Signals
EPS rose 21.4% to $4.66 in Q4.
Risk Factors
Q4 GAAP earnings boosted by $723.9M prior-year impairment absence.
Bullish Signals
Cencora reported a significant 21.4% increase in adjusted diluted earnings per share to $4.66 for the fourth quarter, driven by higher gross profit and the OneOncology acquisition.
The company raised its quarterly dividend by 10% to $0.66 per share and plans substantial additional share repurchases of approximately $1.25 billion for fiscal 2027.
Management projects strong growth in its specialty pharmaceutical segment, expecting revenue to expand 9% to 14% and operating income to grow 18% to 21% in fiscal 2027.
Full-year fiscal results showed robust performance with revenue rising 5.0% to $337.4 billion and adjusted operating income growing 14.0% to $4.8 billion.
Risk Factors
The fourth-quarter GAAP earnings were impacted by the absence of a $723.9 million goodwill impairment charge recorded in the prior-year period, which artificially inflated the current quarter's comparison.
Cencora Inc. reported robust fourth-quarter financial results, with revenue rising 5.5% year-over-year to $88.4 billion and adjusted diluted earnings per share increasing 21.4% to $4.66. The company also declared a quarterly dividend increase to $0.66 per share, signaling confidence in its cash flow generation capabilities for fiscal 2027.
Management has outlined a revised operating framework that places specialty services at the center of its growth strategy. For fiscal 2027, Cencora projects revenue growth between 3% and 5%, with adjusted diluted earnings per share expected to reach $19.40 to $19.75, representing an 8% to 10% increase from the prior year.
The company anticipates that its specialty services segment will outperform its distribution business, forecasting revenue growth of 9% to 14% and operating income growth of 18% to 21%. This outlook assumes the successful closing of the MWI Animal Health merger with Covetrus by March 31, 2027, which is expected to further bolster its specialty portfolio.
Adjusted operating income expanded significantly by 22.1% to $1.2 billion, while adjusted gross profit rose 23.0% to $3.6 billion. The adjusted operating margin improved to 1.41%, reflecting strong operational efficiency and the successful integration of recent acquisitions into the broader business model.
📈 Q4 revenue hit $88.4B, up 5.5% year over year.
💰 Adjusted EPS surged 21.4% to $4.66 per share.
🚀 Quarterly dividend raised to $0.66 for fiscal 2027.
📅 FY2027 adjusted EPS guidance set between $19.40-$19.75.
🤝 MWI Animal Health merger with Covetrus closes March 31, 2027.
📈 Cencora reported fourth-quarter revenue of $88.4 billion, a 5.5% increase year over year.
💰 Adjusted diluted earnings per share surged 21.4% to $4.66 in the latest quarter.
🚀 Management raised the quarterly dividend to $0.66 per share for fiscal 2027.
📅 Fiscal 2027 adjusted diluted EPS guidance is set between $19.40 and $19.75.
🔍 Specialty services segment is projected to grow revenue by 9% to 14% in the upcoming fiscal year.
🤝 The MWI Animal Health merger with Covetrus is expected to close on March 31, 2027.
💹 Adjusted operating income increased 22.1% to $1.2 billion for the quarter ended September 30.
📊 Adjusted gross profit rose 23.0% to $3.6 billion, expanding margins to 1.41%.
🏗️ The company is restructuring its reporting to prioritize Pharmaceutical Distribution and Services alongside Specialty Pharmaceutical and Provider Services.
📉 GAAP diluted earnings per share reached $2.71, a turnaround from a loss of $1.75 in the prior-year quarter.
Cencora Inc. reported robust fiscal fourth-quarter and full-year results, signaling strong earnings momentum as it enters fiscal 2027. Fourth-quarter revenue increased 5.5% year-over-year to $88.4 billion, while adjusted diluted EPS surged 21.4% to $4.66. For the full fiscal year ended September 30, 2026, revenue grew 5.0% to $337.4 billion and adjusted operating income rose 14.0% to $4.8 billion.
The company introduced a new reporting structure with revised segments focused on Pharmaceutical Distribution, Specialty Pharmaceutical, and Provider Services. Management attributed margin expansion in the fourth quarter partly to the acquisition of OneOncology, though lower-margin GLP-1 sales partially offset this benefit. The firm also declared a quarterly dividend increase of 10% to $0.66 per share.
Looking ahead to fiscal 2027, Cencora expects adjusted diluted EPS between $19.40 and $19.75, representing growth of 8% to 10%. Revenue is forecasted to grow 3% to 5%, with segment operating income projected to rise significantly in specialty services. The outlook assumes the closure of the MWI Animal Health merger with Covetrus by March 31, 2027.
📈 Q4 revenue surged 5.5% year-over-year to $88.4 billion.
💰 Adjusted diluted EPS jumped 21.4% to $4.66.
🚀 FY2026 operating income grew 14.0% to $4.8 billion.
💵 Quarterly dividend increased 10% to $0.66 per share.
Cencora (COR) reported quarterly earnings of $4.66 per share, surpassing the consensus estimate of $4.56 and representing a 2.19% surprise. This figure compares favorably to the prior year's adjusted earnings of $3.84 per share. The company has exceeded EPS estimates in three of its last four quarters, demonstrating consistent performance relative to analyst expectations.
The prescription drug distributor posted quarterly revenues of $88.35 billion for the period ended September 2026, beating the consensus estimate by 0.22%. While revenue beat was modest compared to the strong earnings surprise, year-over-year revenue growth remains robust at approximately 5.5% compared to $83.73 billion a year ago. Cencora has topped revenue estimates only once in the last four quarters.
Following the earnings release, Cencora shares have gained about 0.8% since the beginning of the year, though they continue to underperform the S&P 500's 10.6% gain for the same period. The stock currently holds a Zacks Rank #2 (Buy) based on favorable estimate revisions ahead of the report. Investors are watching management commentary and future earnings outlooks to determine if the stock can regain its market momentum.
📈 Cencora beat Q4 EPS estimates by 2.19% at $4.66 per share.
💰 Quarterly revenues hit $88.35 billion, exceeding expectations by 0.22%.
📊 COR has beaten EPS estimates in three of its last four quarters.
📉 Shares gained only 0.8% this year versus S&P 500's 10.6% rise.
🔭 Stock holds Zacks Rank #2 Buy due to favorable earnings revisions.
📈 Cencora reported Q4 earnings of $4.66 per share, beating the consensus estimate of $4.56 by 2.19%.
Cencora Inc. is approaching a pivotal earnings release for its fiscal fourth quarter and full year 2026, scheduled to occur before the opening bell on Wednesday, November 4, 2026. The company, a major player in pharmaceutical distribution and healthcare solutions, will host an investor call starting at 8:30 a.m. Eastern Time featuring CEO Robert P. Mauch and CFO Eva C. Boratto to discuss the upcoming results.
Market sentiment surrounding the stock has shifted positively ahead of this event, driven by an analyst who raised the price target to USD 377. This valuation adjustment reflects a Moderate Buy consensus among analysts, providing investors with a fresh reference point as they anticipate the company's performance in both US and international markets.
Investors are expected to scrutinize the upcoming report for specific guidance on fiscal 2027, operating performance metrics, and the impact of specialty pharmaceutical demand on margins. While the analyst target offers a bullish signal, market participants will weigh this against the actual financial data and management commentary released during the earnings call.
The stock currently trades at EUR 294.30, representing a significant premium to the USD-based analyst target when converted, suggesting potential upside if the company meets or exceeds expectations regarding its core distribution business and healthcare solutions portfolio.
📈 Analysts raised COR price target to USD 377 ahead of Q4 earnings.
📅 COR reports fiscal Q4 and full-year 2026 results Nov 4, 2026.
🗣️ CEO Mauch and CFO Boratto host investor call at 8:30 a.m. ET.
📈 Analysts have raised the price target for Cencora Inc. to USD 377 ahead of its fiscal fourth-quarter earnings release.
📅 The company is scheduled to report fiscal Q4 and full-year 2026 results before the NYSE opens on Wednesday, November 4, 2026.
🗣️ CEO Robert P. Mauch and CFO Eva C. Boratto will participate in an investor call starting at 8:30 a.m. ET to discuss the results.
📊 The current stock price is EUR 294.30, which trades below the USD 377 analyst target when currency conversion is considered.
🔍 Investors are focusing on the company's outlook for fiscal 2027 and its operating performance in US and international businesses.
💊 Market attention is specifically directed toward the effect of specialty pharmaceutical demand on Cencora's profit margins.
Bullish Signals
Analysts raised price target to USD 377 for Moderate Buy.
Key pharma distributor ready to address fiscal 2027 concerns.
Bullish Signals
Analysts have raised the price target to USD 377, signaling a Moderate Buy consensus and providing a bullish valuation reference point ahead of earnings.
The company is positioned as a key player in pharmaceutical distribution and healthcare solutions, with management prepared to address investor concerns regarding fiscal 2027 outlook.
New featuresSoftware integrationAI-generated analysis
Cencora Inc. announced an expansion of its technology ecosystem for health systems on October 28, 2026, focusing on its Accelerate Pharmacy Solutions unit. This operational update introduces new digital tools designed to streamline pharmacy operations and improve patient access by combining existing platforms with partner capabilities.
The new offering integrates Cencora Connect, which provides a centralized dashboard for ordering, marketplace access, and real-time analytics, alongside enhanced eServices for benefit verification and electronic prior authorization. Additionally, the company is collaborating with Plenful on artificial-intelligence workflow automation specifically for 340B programs and rebate management.
This strategic move broadens Cencora's healthcare-solutions platform description but does not include a new earnings forecast or specific transaction value at this time. The company is scheduled to release its fiscal fourth-quarter 2026 results before the New York Stock Exchange opens on November 4, 2026.
Currently, Cencora stock was quoted at 293.80 euros on October 29, 2026, according to Lang & Schwarz data. The announcement represents a non-financial operational development aimed at increasing workflow efficiency within the medical distribution sector.
📅 Cencora expands tech ecosystem with Plenful partnership on Oct 28, 2026.
💻 New platform combines Cencora Connect for pharmacy operations and analytics.
Cencora, Inc. (COR) has announced a definitive agreement to acquire American Oncology Network (AON), a physician-led network comprising over 350 oncology providers located across 21 states. This strategic move is designed to significantly expand Cencora's existing oncology management services organization (MSO) platform, reinforcing its position in the specialized healthcare sector.
The transaction carries an enterprise value of $2.4 billion, with a cash consideration of $2.3 billion at closing. By integrating AON, Cencora aims to deepen its footprint in oncology care delivery and management, leveraging its established infrastructure to scale operations within this high-growth medical specialty.
The acquisition represents a substantial capital deployment intended to drive long-term revenue growth and diversify Cencora's service offerings beyond its traditional pharmaceutical supply chain business. Market reaction has been neutral, with the stock trading flat as investors digest the details of this major mid-sized deal.
📈 Cencora acquires American Oncology Network for $2.4 billion enterprise value.
🏥 Target includes 350+ oncology providers across 21 states.
💰 Deal involves $2.3 billion cash consideration payable at closing.
📊 COR shares trade flat despite significant capital outlay.
📈 Cencora (COR) signed a definitive agreement to acquire American Oncology Network (AON) for an enterprise value of $2.4 billion.
🏥 The target, AON, operates a physician-led network of more than 350 oncology providers spanning 21 states.
💰 The deal includes $2.3 billion in cash consideration payable at closing to complete the acquisition.
🚀 This transaction expands Cencora's oncology management services organization (MSO) platform and strategic capabilities.
📊 The market reaction remains neutral with COR shares trading flat despite the significant capital outlay.
Bullish Signals
Acquired American Oncology Network, expanding oncology services.
Added 350+ oncology providers to scale MSO platform.
Risk Factors
$2.4B acquisition impacts balance sheet and liquidity.
Bullish Signals
Cencora is executing a major strategic expansion by acquiring American Oncology Network, signaling confidence in the oncology management services sector.
The acquisition of AON adds over 350 oncology providers to Cencora's portfolio, directly scaling its MSO platform and market reach.
Risk Factors
The $2.4 billion enterprise value represents a significant cash outflow that will impact Cencora's balance sheet and liquidity in the near term.
Argus Capital raised its price target for Cencora Inc. (COR) from USD 340.00 to USD 380.00 on October 20, 2026, signaling increased analyst confidence in the company's valuation and growth prospects. This bullish adjustment comes amidst a period of significant strategic expansion and strong financial performance for the healthcare distribution giant.
Cencora recently announced a major acquisition agreement to purchase American Oncology Network (AON) for USD 2.4 billion on October 21, 2026. The deal includes contingent value rights of up to USD 100 million and is expected to add to adjusted diluted earnings per share in the second year following closing, subject to regulatory approvals.
The company reported robust third-quarter fiscal 2026 results with revenue reaching USD 84.75 billion, a 5.1% increase year over year. Additionally, Cencora lifted its full-year adjusted diluted earnings per share guidance floor to USD 17.90 on October 22, 2026, indicating strong operational execution and confidence in future profitability.
📈 Argus Capital raised COR price target from $340 to $380 on Oct 20, 2026.
💰 COR agreed to acquire American Oncology Network for $2.4 billion on Oct 21, 2026.
🚀 EPS floor lifted to $17.90 for fiscal 2026 on Oct 22, 2026.
📅 Q4 fiscal 2026 results scheduled before NYSE opens Nov 4, 2026.
📈 Argus Capital raised its price target for Cencora stock from USD 340.00 to USD 380.00 on October 20, 2026.
💰 Cencora agreed to acquire American Oncology Network for a total transaction value of USD 2.4 billion on October 21, 2026.
📊 The company reported Q3 fiscal 2026 revenue of USD 84.75 billion, representing a 5.1% year-over-year increase.
🚀 Cencora lifted its fiscal 2026 adjusted diluted earnings per share floor to USD 17.90 on October 22, 2026.
📅 The company is scheduled to release fourth-quarter fiscal 2026 results before the NYSE opens on November 4, 2026.
🏥 American Oncology Network includes more than 350 oncology providers across 21 states in the United States.
💵 The acquisition of AON is expected to contribute to adjusted diluted earnings per share in the second year after closing.
📉 Cencora stock traded at EUR 296.35 on October 27, 2026, slightly below the previous Xetra close.
🏢 The company operates in the Healthcare and Medical Distribution sector with a market capitalization of USD 63.1 billion.
Bullish Signals
Argus raised price target from $340 to $380.
Bullish Signals
Argus Capital raised its price target for Cencora stock from USD 340.00 to USD 380.00, reflecting positive analyst sentiment regarding the company's valuation.
Cencora successfully reported Q3 fiscal 2026 revenue of USD 84.75 billion, achieving a 5.1% year-over-year growth rate.
The company beat earnings expectations with adjusted diluted EPS of USD 4.48 against a consensus estimate of USD 4.35 in the third quarter.
Cencora lifted its fiscal 2026 adjusted diluted earnings per share guidance floor to USD 17.90, demonstrating strong operational performance.
The acquisition of American Oncology Network is projected to add to adjusted diluted earnings per share in the second year post-closing.
Cencora secured a strategic agreement to acquire a physician-led network with over 350 oncology providers across 21 states for USD 2.4 billion.
Cencora Inc. has agreed to acquire American Oncology Network for an enterprise value of USD 2.4 billion, marking a significant expansion in its oncology portfolio. The deal structure includes USD 2.3 billion in cash at closing and contingent value rights of up to USD 100 million, with Cencora expecting to pay approximately USD 1.7 billion if eligible shareholders retain a 25 percent stake via an equity rollover.
This acquisition targets American Oncology Network, which operates more than 350 oncology providers across 21 states. Cencora already holds a 4 percent stake in the network prior to this transaction. The agreement is currently subject to necessary regulatory clearances and shareholder approval before it can be finalized.
Following the announcement of the oncology deal, Cencora raised its fiscal 2026 adjusted earnings per share (EPS) floor to USD 17.90, positioning itself at the high end of its previously guided range of USD 17.75 to USD 17.95. Management expects the acquisition to contribute positively to adjusted diluted EPS in the second year following the closing of the transaction.
Cencora recently reported strong fiscal third-quarter results with adjusted EPS of USD 4.48, beating the consensus estimate of USD 4.35, and revenue reaching USD 84.75 billion. The company plans to release its fiscal fourth-quarter results before the New York Stock Exchange opens on November 4, 2026.
Cencora's stock is primarily listed on the NYSE with a market capitalization of USD 63.2 billion as of late October 2026. While trading at EUR 296.75 in European markets, the company maintains a strong presence in the healthcare distribution sector.
📈 Cencora agreed to acquire American Oncology Network for USD 2.4 billion enterprise value.
💰 Deal includes USD 2.3 billion cash plus up to USD 100 million in contingent rights.
🏥 Target operates over 350 oncology providers across 21 states.
📊 Cencora raised fiscal 2026 adjusted EPS floor to USD 17.90 following the deal.
⚖️ Transaction remains subject to regulatory clearances and shareholder approval.
📈 Cencora agreed to acquire American Oncology Network for an enterprise value of USD 2.4 billion.
💰 The deal includes USD 2.3 billion at closing plus contingent value rights of up to USD 100 million.
🏥 American Oncology Network operates over 350 oncology providers across 21 states.
📊 Cencora raised its fiscal 2026 adjusted EPS floor to USD 17.90 following the deal announcement.
🚀 Management expects the acquisition to add to adjusted diluted EPS in the second year after closing.
💹 Q3 2026 results showed adjusted EPS of USD 4.48, beating the consensus estimate of USD 4.35.
📈 Revenue for fiscal third quarter reached USD 84.75 billion.
🗓️ Fiscal fourth-quarter results are scheduled to be released before the NYSE opens on November 4, 2026.
🏢 Cencora already owns a 4 percent stake in American Oncology Network prior to this acquisition.
⚖️ The transaction remains subject to regulatory clearances and shareholder approval.
Bullish Signals
Acquired American Oncology Network for USD 2.4B.
Raised FY2026 EPS guidance to USD 17.90.
Q3 adjusted EPS beat at USD 4.48.
Revenue reached USD 84.75 billion in Q3.
Bullish Signals
Cencora agreed to a USD 2.4 billion oncology deal to acquire American Oncology Network, expanding its provider footprint across 21 states.
Management raised fiscal 2026 adjusted EPS guidance to USD 17.90, placing the target at the high end of the previous range.
The company expects the acquisition to add to adjusted diluted earnings per share in the second year after closing.
Cencora beat Q3 consensus estimates with adjusted EPS of USD 4.48 versus a USD 4.35 expectation.
Revenue for the fiscal third quarter reached USD 84.75 billion, demonstrating strong top-line performance.
Cencora Inc. has agreed to acquire American Oncology Network (AON) in a transaction valued at approximately USD 2.40 billion. The deal, announced on October 21, 2026, involves Cencora purchasing the equity interests in AON that it does not already own, as the company currently holds about 4% of AON's shares.
The total transaction value consists of a base payment of USD 2.30 billion at closing, plus contingent value rights of up to USD 100 million. The acquisition is subject to customary closing conditions, including necessary regulatory clearances and approval from AON stockholders.
Cencora stock was trading at EUR 297.50 during weekend sessions on October 25, 2026, with a bid of EUR 296.90 and an ask of EUR 298.10 reported by Lang & Schwarz. The company operates a large pharmaceutical distribution center utilizing trucks and forklifts for daily medication logistics.
📈 Cencora agreed to acquire American Oncology Network for USD 2.40 billion on October 21, 2026.
💰 Deal includes USD 2.30 billion base payment plus up to USD 100 million in contingent rights.
🤝 Cencora will acquire remaining equity after holding approximately 4% of American Oncology Network.
⚖️ Acquisition subject to regulatory clearances and AON stockholder approval.
📊 Cencora stock traded at EUR 297.50 with a bid of EUR 296.90 on October 25, 2026.
📈 Cencora agreed to acquire American Oncology Network in a USD 2.40 billion transaction announced on October 21, 2026.
💰 The deal includes a base payment of USD 2.30 billion at closing plus contingent value rights of up to USD 100 million.
🤝 Cencora currently holds approximately 4% of American Oncology Network and will acquire the remaining equity interests.
⚖️ The acquisition is subject to customary closing conditions, including regulatory clearances and AON stockholder approval.
📊 Cencora stock traded at EUR 297.50 during weekend sessions on October 25, 2026, with a bid of EUR 296.90.
🚛 The company operates a large pharmaceutical distribution center utilizing trucks and forklifts for daily medication logistics.
Bullish Signals
Acquired American Oncology Network for $2.4B.
Deal includes up to $100M contingent value rights.
Consolidates position in oncology distribution market.
Risk Factors
Deal requires regulatory clearance and shareholder approval.
$2.4B acquisition impacts balance sheet and cash flow.
Bullish Signals
Cencora is executing a major strategic expansion by acquiring American Oncology Network in a USD 2.40 billion deal, significantly increasing its oncology capabilities.
The transaction includes contingent value rights of up to USD 100 million, providing potential upside beyond the base closing price.
The acquisition allows Cencora to consolidate its position in the specialized oncology distribution market through American Oncology Network.
Risk Factors
The acquisition is subject to customary closing conditions, including regulatory clearances and AON stockholder approval, which could delay or prevent completion.
The deal value of USD 2.40 billion represents a significant capital outlay that will impact Cencora's balance sheet and cash flow in the short term.
Cencora Inc. has agreed to acquire the American Oncology Network, a significant expansion in its oncology distribution capabilities. The oncology network operates across 21 states and includes more than 350 oncology providers, marking a strategic move to deepen Cencora's footprint in specialized pharmaceutical logistics.
The transaction is currently subject to customary closing conditions, including necessary regulatory clearances and stockholder approvals. This acquisition aligns with Cencora's broader strategy of integrating specialized healthcare networks into its distribution infrastructure.
Cencora continues to operate a large pharmaceutical distribution center utilizing trucks, forklifts, and daily medication logistics to support its growing network of clients and providers across the United States.
📈 COR agreed to acquire American Oncology Network.
🏥 Acquired network spans 21 US states.
👥 Deal includes over 350 oncology providers.
⚖️ Closing requires regulatory and stockholder approvals.
🚛 COR manages large pharmaceutical distribution logistics.
📈 Cencora Inc. announced an agreement to acquire the American Oncology Network.
🏥 The acquired oncology network operates across 21 states in the United States.
👥 The target network includes more than 350 oncology providers.
⚖️ The transaction remains subject to customary closing conditions, including regulatory clearances and stockholder approvals.
🚛 Cencora operates a large pharmaceutical distribution center with trucks and forklifts for daily medication logistics.
Bullish Signals
Acquired American Oncology Network to expand oncology sector.
Added 350+ providers across 21 states for distribution.
Bullish Signals
Cencora has secured an agreement to acquire the American Oncology Network, expanding its presence in the oncology sector.
The acquisition includes a network of over 350 oncology providers operating across 21 states, significantly increasing Cencora's distribution reach.
Cencora, Inc. (NYSE: COR) announced a definitive agreement to acquire American Oncology Network (AON), a physician-led network comprising over 350 oncology providers across 21 states. The deal aims to expand Cencora's Managed Services Organization (MSO) platform and strengthen its presence in twelve additional states, thereby enhancing support for independent oncology practices.
The transaction values AON at an enterprise value of $2.4 billion, with Cencora acquiring the remaining equity interests it does not currently hold. Assuming certain stockholders participate in an equity rollover, Cencora expects to pay approximately $1.7 billion at closing to increase its ownership stake to 75%, with up to $100 million in contingent value rights (CVRs) payable upon meeting specific conditions.
Cencora updated its fiscal year 2026 financial guidance to reflect the strength of its U.S. Healthcare Solutions segment, raising adjusted diluted EPS expectations to at least $17.90. Management expects the acquisition to be accretive to adjusted diluted earnings per share in the second year post-closing, signaling confidence in the strategic value of integrating AON's physician-led model.
The acquisition is subject to customary closing conditions, including regulatory clearances and stockholder approvals. Cencora plans to discuss its expectations for fiscal 2027 on its upcoming fourth quarter earnings call, maintaining confidence in continued growth within its Healthcare Solutions segments.
📈 Cencora acquires American Oncology Network for $2.3B plus up to $100M in CVRs.
🌍 Deal expands Cencora's MSO platform into twelve additional states with 350+ oncology providers.
📉 Raised FY2026 adjusted diluted EPS guidance to at least $17.90 reflecting segment strength.
🚀 Acquisition expected to be accretive to Cencora's adjusted diluted EPS in second year.
⚖️ Transaction subject to regulatory clearances and AON stockholder approvals before closing.
📈 Cencora signed a definitive agreement to acquire American Oncology Network (AON), a physician-led network of over 350 oncology providers across 21 states.
💰 The transaction values AON at an enterprise value of $2.4 billion, consisting of $2.3 billion at closing and up to $100 million in contingent value rights (CVRs).
🤝 Cencora currently holds approximately 4% of AON equity and plans to acquire the remaining interests, potentially increasing its stake to 75% via an equity rollover.
📉 Financial guidance update: Cencora raised adjusted diluted EPS expectations for fiscal year 2026 to at least $17.90, reflecting strength in its U.S. Healthcare Solutions segment.
🚀 Strategic impact: The acquisition is expected to be accretive to Cencora's adjusted diluted EPS in the second year post-closing.
🌍 Expansion scope: The deal expands Cencora's MSO platform and presence across twelve additional states, strengthening its support for independent oncology practices.
⚖️ Regulatory status: The transaction is subject to customary closing conditions, including receipt of required regulatory clearances and AON stockholder approvals.
👥 Leadership alignment: Todd Schonherz, CEO of AON, noted that Cencora understands the mission of high-quality, accessible cancer care delivered close to home.
📅 Forward-looking outlook: Cencora will discuss expectations for fiscal 2027 on its fourth quarter earnings call scheduled for November 4, 2026.
Bullish Signals
Acquired AON to expand oncology platform and strengthen patient access.
Risk Factors
Deal delayed by regulatory/AON approval risks.
Bullish Signals
Cencora announced a definitive agreement to acquire American Oncology Network (AON), expanding its physician-led oncology MSO platform and strengthening patient access to high-quality care.
The acquisition of AON is expected to be accretive to Cencora's adjusted diluted EPS in the second year post-closing, indicating immediate financial value creation.
Cencora updated its fiscal year 2026 guidance to raise adjusted diluted EPS expectations to at least $17.90, reflecting strong performance in its U.S. Healthcare Solutions segment.
The deal values AON at an enterprise value of $2.4 billion, with Cencora acquiring the remaining equity interests to increase its ownership stake to 75%.
Risk Factors
The transaction is subject to customary closing conditions, including receipt of required regulatory clearances and AON stockholder approvals, which could delay or prevent completion.
Baird Capital raised its price target for Cencora Inc. (COR) from USD 370.00 to USD 373.00 on October 12, 2026, maintaining an Outperform rating. The analyst firm cited the company's strong fiscal third-quarter performance as a key driver for the valuation adjustment, providing fresh upside potential ahead of the upcoming fourth-quarter earnings release scheduled for November 4, 2026.
Cencora reported robust financial results for the quarter ended June 30, 2026, with fiscal revenue reaching USD 84.80 billion, representing a 5.10% year-over-year increase. Adjusted operating income surged by 17.00%, while adjusted earnings per share climbed 12.00%, reflecting improved operational efficiency and margin expansion within the medical distribution sector.
Following the strong quarterly results, Cencora management raised its full-year fiscal 2026 adjusted earnings-per-share guidance to a range of USD 17.75-17.95 from the previous estimate of USD 17.70-17.90. This upward revision signals confidence in sustained demand across its US and international healthcare solutions businesses, positioning the stock favorably relative to its current trading price.
📈 Baird raised COR price target to USD 373 with Outperform rating.
💰 COR Q3 revenue hit USD 84.8B, up 5.10% year-over-year.
📊 COR adjusted operating income rose 17% and EPS grew 12%.
Cencora Inc. reported strong fiscal third-quarter results, with revenue rising 5.10% to USD 84.80 billion for the period ended June 30, 2026. GAAP diluted earnings per share increased significantly to USD 3.94 from USD 3.52 in the prior-year quarter, reflecting solid operating progress across its distribution and patient-access services.
Following these results, investment firm Robert W. Baird raised its price target for Cencora stock from USD 370.00 to USD 373.00 on October 12, 2026. The analyst move provides a fresh bullish reference point as investors await the company's upcoming fiscal fourth-quarter results scheduled for release on November 4, 2026.
Cencora continues to serve pharmaceutical manufacturers, hospitals, and pharmacies through its extensive distribution network. With a market capitalization of USD 63.2 billion, the healthcare logistics giant trades under the ticker COR on the NYSE, maintaining a 52-week range between USD 244.82 and USD 377.54 as of mid-October 2026.
📈 Cencora Q3 revenue rose 5.1% to USD 84.8 billion.
💰 GAAP EPS increased to USD 3.94 from prior year.
🏢 Distributes products to hospitals, pharmacies, and healthcare providers.
💵 Market cap reached USD 63.2 billion as of Oct 12.
🗓️ Q4 results scheduled for release on November 4, 2026.
📈 Cencora reported fiscal third-quarter revenue of USD 84.80 billion, representing a 5.10% increase from the prior-year quarter.
💰 GAAP diluted earnings per share grew to USD 3.94, up from USD 3.52 in the same period last year.
📊 Robert W. Baird raised its price target for Cencora stock from USD 370.00 to USD 373.00 on October 12, 2026.
🗓️ The company plans to release fiscal fourth-quarter results before the NYSE open on November 4, 2026.
🏢 Cencora serves pharmaceutical manufacturers, hospitals, pharmacies, and other healthcare providers through distribution services.
💵 As of October 12, 2026, the company had a market capitalization of USD 63.2 billion.
📉 The stock traded within a 52-week range of USD 244.82 to USD 377.54 as of mid-October 2026.
Cencora Inc. (NYSE: COR) traded at USD 324.29 on October 9, 2026, reflecting a slight gain of 0.99% against the prior close. The company maintains a market capitalization of USD 63.1 billion and trades at a price-to-earnings ratio of 24.08. Trading volume for the session was notably subdued at 321,889 shares, representing a significant decline compared to the recent average volume.
The stock is currently positioned within its 52-week trading range, situated above the yearly low but below the period high of USD 377.54. Investors are awaiting the release of Cencora's fourth-quarter fiscal 2026 results, which the company scheduled to report on November 4, 2026, before the opening bell on the New York Stock Exchange.
The article provides a snapshot of Cencora alongside its major competitors in the medical distribution sector, including Cardinal Health and McKesson Corporation. While these peers showed mixed performance with varying P/E ratios, the primary focus remains on Cencora's current valuation metrics and upcoming earnings event.
📈 COR stock rose 0.99% to close at USD 324.29 on October 9, 2026.
💰 COR holds a market cap of USD 63.1 billion with a P/E of 24.08.
📉 Trading volume for COR was significantly lower than average at 321,889 shares.
📅 COR will report Q4 fiscal 2026 earnings on November 4, 2026.
🏥 COR operates as a major pharmaceutical distribution center using logistics for delivery.
📈 Cencora stock closed at USD 324.29 on October 9, 2026, marking a 0.99% increase versus the previous trading session.
💰 The company holds a substantial market capitalization of USD 63.1 billion with a P/E ratio of 24.08.
📉 Trading volume was significantly lower than average at 321,889 shares, indicating lighter turnover compared to the norm.
📅 Cencora plans to report its fourth-quarter fiscal 2026 earnings results on November 4, 2026.
📊 The stock trades within its 52-week range between USD 244.82 and USD 377.54.
🏥 Cencora operates as a major pharmaceutical distribution center utilizing logistics for daily medication delivery.
Cencora stock gained 0.99% to reach USD 324.29, demonstrating positive momentum in the healthcare distribution sector.
The company maintains a robust market capitalization of USD 63.1 billion, reflecting strong investor confidence and scale.
Risk Factors
Trading volume was materially lighter than the recent average, dropping by approximately 75% which may indicate reduced immediate interest or liquidity.
The stock price is currently trading below its 52-week high of USD 377.54, suggesting it has not yet reached its yearly peak valuation.
Seeking Alpha analyst Albert Anthony reaffirms a buy rating for Cencora, Inc. (COR), citing supportive business and macro fundamentals despite recent market underperformance. The analyst highlights the company's investment-grade credit rating, positive operating cash flow, dividend safety, and an improved operating margin as key pillars of the investment thesis.
The article notes that Cencora operates with a global distribution footprint and a market capitalization exceeding $58 billion. While the healthcare supply-chain sector faces specific risks such as tariffs, regulatory actions, and potential disruptions, the analyst maintains that these do not outweigh the current positive outlook for the stock at its present price levels.
The commentary suggests that Cencora is well-positioned to capitalize on growing healthcare supply-chain needs. The analysis focuses on fundamental metrics rather than short-term volatility, emphasizing the durability of the company's financial position and its strategic importance within the broader healthcare logistics landscape.
📈 Seeking Alpha analyst reaffirms buy rating for COR on strong fundamentals.
Cencora Inc. reported a strong fiscal third quarter in 2026, with adjusted earnings per share of USD 4.48 beating the consensus estimate of USD 4.37 by 2.52%. The company also posted GAAP earnings per share of USD 3.94 and total revenue of USD 84.75 billion, representing a 5.10% year-over-year increase. Adjusted operating income rose significantly by 17.00% to USD 1.24 billion, driven largely by growth in its U.S. Healthcare Solutions segment.
The core driver of this performance was the U.S. Healthcare Solutions division, which generated USD 74.90 billion in revenue, up 4.90% year over year. This segment's operating income increased by 15.90% to USD 966.20 million, supported specifically by volume growth in specialty products, including high-demand GLP-1 medicines. Despite a notable increase in net interest expense of 72.00% to USD 140.70 million and the loss of an oncology customer, the company demonstrated robust execution.
Following these results, Cencora raised its fiscal 2026 adjusted earnings guidance to a range of USD 17.75-17.95 per share, up from the previous forecast of USD 17.70-17.90. The company also provided forward-looking revenue growth expectations of 4.00-6.00% and adjusted operating income growth of 13.00-14.00% for the full year. Analyst sentiment remains positive, with 13 analysts maintaining Buy ratings and an average price target of USD 370.85.
📈 Cencora beat Q3 EPS estimates by 2.52% at USD 4.48.
💰 Revenue grew 5.10% YoY to USD 84.75 billion driven by volume.
🚀 Operating income surged 17.00% to USD 1.24 billion on efficiency gains.
⚠️ Net interest expense spiked 72.00% to USD 140.70 million.
Cencora Inc. (COR) saw its shares trade at EUR 54.84 in pre-market activity on September 30, 2026, representing a modest gain of 0.49 percent against the previous day's closing price of EUR 54.57. The stock is listed on the New York Stock Exchange under the symbol COR.
The company announced a significant corporate governance change with the election of Robert E. Sanchez to its Board of Directors. This appointment, effective October 1, 2026, expands the board from ten to eleven members and brings in an independent director with extensive experience in logistics and transportation.
📈 COR stock rose 0.49% pre-market on September 30, 2026.
👔 Robert E. Sanchez appointed as independent director effective October 1.
🏢 Board size increased from ten to eleven members.
🚛 Sanchez joins with Ryder System executive chair experience.
📄 SEC filing confirms new independent director appointment.
📈 Cencora stock traded at EUR 54.84 pre-market on September 30, 2026, up 0.49 percent from the prior close.
👔 The company appointed Robert E. Sanchez as an independent director to its Board of Directors.
📅 The new board appointment by Cencora takes effect on October 1, 2026.
🏢 The election increases the total number of board members from ten to eleven.
🚛 Robert E. Sanchez brings experience as executive chair of Ryder System, Inc. to the Cencora board.
📄 Cencora filed an announcement with the SEC regarding the new independent director appointment.
Bullish Signals
Board size increased to 11 members with new independent director.
Added seasoned executive chair with prior Ryder System CEO experience.
Bullish Signals
Cencora expanded its Board of Directors by electing Robert E. Sanchez as an independent director, increasing the board size from ten to eleven members.
The appointment of Robert E. Sanchez adds a seasoned executive chair with prior CEO experience at Ryder System, Inc. to the company's leadership team.
On September 25, 2026, Cencora, Inc. filed a Form 8-K with the SEC to announce the appointment of Robert E. Sanchez to its Board of Directors. The appointment is effective October 1, 2026, increasing the board size from ten to eleven members in accordance with the company's Amended and Restated Bylaws.
Mr. Sanchez will receive compensation and benefits consistent with the Company's policy for non-employee directors, including quarterly cash disbursements and a pro-rated annual equity award covering the period from October 1, 2026, until the 2027 Annual Meeting of Stockholders. He has not yet been designated to any board committees.
The filing confirms there are no reportable transactions involving Mr. Sanchez under Item 404(a) of Regulation S-K and no familial ties with current directors or executive officers. Cencora issued a news release regarding the appointment, which was attached as Exhibit 99.1 to the SEC filing.
📅 Cencora appoints Robert E. Sanchez to Board effective Oct 1, 2026.
👥 Board size expands from ten to eleven members.
💰 New director receives standard compensation including pro-rated equity award.
🚫 No committee roles assigned to Mr. Sanchez initially.
📝 No related-party transactions or familial ties for new director.
📅 Cencora appointed Robert E. Sanchez to its Board of Directors effective October 1, 2026.
👥 The board size expanded from ten to eleven members following the appointment.
💰 Mr. Sanchez will receive standard non-employee director compensation including a pro-rated equity award.
🚫 No committee roles have been assigned to Mr. Sanchez at this time.
📝 There are no reportable related-party transactions or familial ties involving the new director.
Bullish Signals
Board expanded to 11 members with Robert E. Sanchez.
Appointment aligns with Amended and Restated Bylaws.
Bullish Signals
Cencora has successfully expanded its Board of Directors to eleven members, adding Robert E. Sanchez as a non-employee director effective October 1, 2026.
The appointment aligns with the company's Amended and Restated Bylaws, demonstrating adherence to corporate governance standards.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)